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Increased renal epithelial proliferation is manifested in multiple ways in the cystic disorders. In ADPKD hyperplasia includes polyps of the cyst-lining epithelium [3] , microscopic renal adenomas [4] and increased proliferation and responsiveness of cultured ADPKD cyst epithelia to mitogens such as EGF [5] . Similarly, in tuberous sclerosis (TS), renal cysts demonstrate hyperplastic epithelia with nodular extensions into the lumen and angiomyolipomas [6] . The renal cystic epithelia in Von-Hippel-Lindau (VHL) disease display a histopathologic continuum from normal to hyperplastic to malignant epithelia [7] . Moreover, in VHL and TS the responsible genes are mutated tumor suppressor genes [8, 9] , confirming the hypothesis that increased cell proliferation can lead to cyst formation. This concept is supported by the observation that renal cysts occur in transgenic animal models in which c-myc or HrasT24 is in the transgene [10, 11] . The question of an interrelationship of such oncogenes with genes regulating cell death has also been raised by recent experimental studies [12] .
Increased cell proliferation alone would be expected to result only in the solid tumors seen in these disorders. It is apparent that fluid secretion is also necessary to form a fluid-filled cyst. Direct evidence comes from in vitro studies of MDCK cells suspended in collagen matrix [13] . In defined medium alone, these cells do not proliferate or form cysts. If EGF is added, dense, solid balls of cells form. If a cAMP-agonist is added, which stimulates both cell proliferation and fluid secretion, cysts are formed [13] . This fluid secretion by cyst epithelia is demonstrated by studies on intact cysts excised from human ADPKD kidneys which vigorously secrete fluid when they remain filled with the original cyst fluid or when stimulated with a cAMP agonist [14] . The secretory and cystogenic capacity of ADPKD cyst fluid is also demonstrated both by its ability to stimulate fluid secretion by monolayers of MDCK and human kidney cortex cells in cell culture and to induce cyst formation in both these cell types in collagen matrix [13] .
Clinically this secretory capacity of cyst epithelia is seen when cysts are punctured and drained; they will rapidly reaccumulate fluid if the epithelium is not altered with alcohol sclerosis [15, 16] . The critical role of fluid secretion in cystogenesis offers a potential for ultimate treatment of these disorders with agents which inhibit epithelial fluid secretion.
Alterations of the extracellular matrix in the cystic disorders are suggested by the splitting, duplication and lamination of tubular basement membranes (BM) seen in early stages of ADPKD [17] ; the thickened BM of cyst-lining epithelia at later stages of ADPKD [18] ; the thickened tubular BM in a drug-induced rat model of PKD [19] , and extremely thin, attenuated tubular BM adjacent to thickened and laminated areas in patients with juvenile medullary cystic disease [20] . In cell culture ADPKD epithelia elaborate a grossly abnormal-appearing extracellular matrix [18] . Some studies have shown reduced de novo synthesis of proteoglycans by human ADPKD cyst-derived epithelia and an altered composition of various proteoglycan fractions [21] . Finally, the array of systemic disorders present in a disease like ADPKD is compatible with a matrix disorder. One possible explanation for these alterations in proliferation, secretion and matrix in cystic epithelia is that cyst epithelium is either incompletely differentiated or partly dedifferentiated. In hereditary or developmental disorders, a block in the normal tubular development could lead to continued cell growth without terminal differentiation, whereas an insult to mature kidneys could cause dedifferentiation [22] . This concept is supported by the observation of an immature phenotype of cyst-lining epithelia, the abnormal expression of developmentally regulated genes in cpk mice [23] , the overexpression of differentiation antigens and growth-related genes in human ADPKD cells [24] , reduced distal tubular EGF expression with consequent lack of collecting duct maturation in cpk [25] and pcy mice [26] , and persistence of fetal proteins in human ADPKD and ARPKD epithelia [27, 28] . Abnormal responsiveness to growth factors [5, 18] , suggesting yet a third gene [37] . Recently, the ADPKD1 gene has been identified; but the function of the protein has not been determined (note added in proof, A). There are phenotypic differences between ADPKD1 and AD-PKD2, with ADPKD2 individuals developing hypertension and ESRD at an older age than ADPKD1 individuals (mean age at ESRD 69.4 1.7 vs. 56.7 1.9 years) [38] . However, even within ADPKD1 families there is considerable variability both in the occurrence of extrarenal manifestations and in the severity of the renal disease [39, 40] . For example, within a family, some members may reach ESRD more than 30 years earlier than others [40] . In addition, some families have one or more offspring who are diagnosed in utero or in the first year of life from a mother with typical adult onset disease [41] . This phenotypic variability within families has both clinical and scientific implications. Clinically it means that when counselling ADPKD families one cannot assume the disease will have a similar course in a given family. From a more scientific perspective, this variability is of interest because of its similarities with diseases such as fragile-X syndrome, myotonic dystrophy, and Huntington's disease [42] [43] [44] . The underlying molecular mechanism in these diseases is unstable DNA, with varying numbers of triplet repeats within the gene in different family members relating to different age of onset and disease severity [45] [46] [47] . Whether a similar mechanism is operative in ADPKD or whether this intrafamilial variability is due to the interaction of the ADPKD genes with other modifying genes or environmental factors is not yet clear. However, the identification of the ADPKD1 gene will permit this question to be answered in ADPKD1 families. The unstable DNA would also explain the apparent high spontaneous mutation rate and the variability in extrarenal manifestations. This question of etiology of phenotypic variability is of interest not only in ADPKD but also in the other systemic renal cystic diseases, particularly TS, which shows many of the same features of differing age of onset, variable phenotypic expression and severity of disease.
Diagnosis, clinical manifestations, and management considerations. The mainstay for diagnosing ADPKD is ultrasonography. Its only limitation is that it relies on the presence of renal cysts to define the gene carrier state. In ADPKD1 families 64% of affected children under the age of 10 years and about 90% of teenagers between 10 and 19 years who are presumed gene carriers have detectable renal cysts [48] . technique is shown in Figure 1 . An 18-year-old woman who had no cysts by ultrasonography had approximately a 10% chance of carrying the gene (if she was in an ADPKD1 family). She wished a more precise answer regarding her gene status. This could only be obtained with gene linkage; this could be performed in her because she had 2 other affected family members which were necessary to identify the marker haplotype travelling with the ADPKD gene in this family.
Before performing gene linkage or before any screening is done, patients must be competently informed about the potential psychological and insurance implications of a positive diagnosis. These are issues of particular concern in screening children [49] . Because of the expense of gene linkage techniques, the need to involve other family members and the reliability of ultrasonography, gene linkage will likely be limited to circumstances in which family planning would be altered, or for potential kidney donors when ultrasound findings are nondiagnostic [49, 50] . Although the need to involve other family members will not be required eventually for the ADPKD1 gene, the other advantages of ultrasonography will still remain.
ADPKD is a systemic disease with both renal and extrarenal manifestations (Tables 2 and 3 ). The anatomic renal manifestation is diffuse renal cystic disease; the cysts are distributed throughout the cortex and medulla (Fig. 2) . The common clinical renal manifestations are chronic flank and/or back pain, hematuna, infection, nephrolithiasis and hypertension [51] . Pain, hematuna and hypertension occur more often in patients with larger kidneys [52] [53] [54] . The relationship between renal and/or cyst size and pain is demonstrated by the long-term relief achieved in patients with disabling pain who undergo cyst decompression [55, 56] . Both microscopic and gross hematuria occur in ADPKD; acute episodes of macroscopic hematuria can be caused by cyst hemorrhage, infection or nephrolithiasis. Cyst hemorrhages are best managed conservatively, with bed rest and mild analgesics [57] . If a particular activity reproducibly provokes hematuria, this activity should be discouraged since repeated episodes of gross hematuria have been associated with decreased renal function [53] .
Nephrolithiasis occurs in 20 to 36% of ADPKD patients [58, 59] . This high frequency may be related to both urinary stasis secondary to cyst compression of tubules and metabolic factors such as hypocitraturia, hyperoxaluria and hyperuricemia which have been found to occur in ADPKD patients with nephrolithiasis and normal renal function [58] .
Infection can occur as lower urinary tract infection, renal interstitial infection (pyelonephritis), renal cyst infection or pennephric abscess. Although lower UTI and pyelonephritis are managed as in the general population, renal cyst infection requires the administration of lipid-soluble antibiotics such as trimethoprim-sulfamethoxazole, chloramphenicol or ciprofloxacm which can penetrate cyst walls [57] .
Hypertension is an early and common manifestation of ADPKD. Sixteen percent of children under the age of 18 years have blood pressures above the 95th percentile for age-and gender-matched children [601 and 60 to 75% of adults are hypertensive before impairment of renal function [51] . Moreover, in one study ADPKD adults between 15 and 25 years of age had significantly elevated left ventricular mass compared to controls, attesting to the biologic significance of the blood pressure elevation early in the course of the disease [611. Numerous studies have shown that the renin-angiotensin system is activated in patients with ADPKD [62] [63] [64] [65] [66] , presumably via disruption of the renal [67, 68] . Factors which have been reported to contribute to a faster rate of progression are the ADPKD1 genotype, male gender, younger age at diagnosis, hypertension, increased left ventricular mass, hepatic cysts in women, three or more pregnancies, multiple episodes of gross hematuria, urinary tract infections in men, and increased renal volume [38, 52, 68, 691 . Some of these factors such as hypertension, infection and pregnancies are amenable to intervention and their modification may improve the renal outcome of ADPKD patients. Once ESRD has been reached, ADPKD patients are good candidates for hemo-or peritoneal dialysis and renal transplantation [70] .
The most common extrarenal manifestation is hepatie cysts which are rarely seen in children but increase with age, declining renal function, and parity in women. Seventy-seven percent of patients over the age of 60 have hepatic cysts [71] . Massive hepatic cystic disease occurs predominantly in women [72, 73] . This observation and the relationship of disease severity to parity suggest a pathogenetic role for female steroid hormones in hepatic cystogenesis [72] . Liver function is normal unless a complication such as infection or malignancy is present [73, 74] . For the rare patient with a grossly enlarged liver and disabling pain, surgical resection and decompression is a therapeutic option [75] . Although congenital hepatic fibrosis is generally associated with ARPKD, some cases have been described in association with ADPKD [76] [77] [78] , and even Caroli's disease coexisting with congenital hepatic fibrosis and polycystic liver and kidney disease in the same patient has been reported [79] . The other common gastrointestinal tract manifestation is coIonic diverticula and associated complications which occur more often in ADPKD-ESRD patients compared to ESRD patients with other diseases and to the general population [51, 80] . Hernias also occur more often than in the general population [51] . The most devastating extrarenal manifestation is a ruptured intracranial aneurysm (ICA). Three recent prospective studies have shown a frequency of ICA in asymptomatic ADPKD patients between 5 and 11% [81] [82] [83] . There may be family clustering of ruptured ICA [83] [84] [85] [86] , and rupture of an ICA in ADPKD seems to occur at a younger age and with smaller aneurysms than in the general population [82, 83, 87] . Screening for ICA by noninvasive methods such as dynamic CT or magnetic resonance angiography currently is recommended only for patients with a family history of ruptured ICA, patients with a previous ruptured ICA, those engaged in an activity where loss of consciousness would place them or others at extreme risk, or those who are undergoing a surgical intervention likely to be associated with hemodynamic instability with hypertension [87] [88] [89] [90] , A flow chart of our current recommendations is displayed in Figure 3 .
Cardiac valvular abnormalities are also common in ADPKD.
Mitral valve prolapse has been shown in two prospective echocardiographic studies to occur in about 25% of ADPKD patients, compared to only 2% of controls [91, 92] . This is often associated with atypical chest pain or palpitations [91, 92] . The natural history of these cardiac valvular lesions is uncertain, but some ADPKD patients have required valve replacements [93] . In general, an assessment for extrarenal manifestations should occur only when clinically indicated.
Tuberous sclerosis
Epidemiology and genetics. Tuberous sclerosis (TS) is characterized by multiple hamartomas, which are benign congenital tumors composed of abnormally arranged and differentiated tissues in brain, retina, skin, heart, kidneys, liver, lung and bone. It is much more common than previously thought with recent prevalence estimates of 1:5800 to 1:10000 [94] [95] [96] . Inheritance is autosomal dominant with genetic heterogeneity. Linkage to chromosome 9 has been established for about one-third of families [97] ; linkage has also been reported to markers on chromosomes 11, 12 and 16 [98] [99] [100] , but recent evidence has questioned the existence of TS genes on chromosomes 11 and 12 [9] . In most, if not all multigeneration families the disease appears to be caused by a mutation either on chromosome 9 or 16 [9] . Recently the TS gene located on chromosome 16 (TSC2) has been identified, and interestingly lies in the same region as the ADPKD1 gene [9] . The protein product, tuberin, has homology with proteins involved in cell proliferation and differentation [9] .
About two-thirds of cases seem to be new mutations in that they have a negative family history [94, 95, 99, 101] , but as in ADPKD, a negative family history could reflect minimal disease in parents who remain undiagnosed rather than a true new mutation. TS is characterized by extreme variability of phenotypic expression, with some members of a family having fatal disease complications and others being normal on routine clinical examination [101, 102] .
Diagnosis, clinical manifestations and management considerations. The diagnosis of TS is usually made by a typical constellation of clinical findings [95, 103] . These include skin lesions such as facial angiofibromas (adenoma sebaceum), hypomelanotic macules, and ungual fibromas. Central nervous system manifestations, some of which are considered pathognomonic and are best diagnosed by CT or MRI of the brain, include multiple cortical tubers, subependymal glial nodules, giant cell astrocytoma, and retinal astrocytomas [95] . Seizures can occur in up to 80% of patients [94, 95, 102] , and about 50-60% of patients are mentally retarded [94, 95, 102] . The heart may be affected by benign rhabdomyomas, the liver by angiomyolipomas, and the lung by malignant lymphangiomyomatosis.
Renal manifestations occur in 50 to 100% of patients, most often as multiple and bilateral angiomyolipoma, with or without cysts, and rarely as renal cell carcinoma [6] . TS mimicking ADPKD has repeatedly been described in adults and children [104] [105] [106] [107] . Tuberous sclerosis should be entertained as an alternative diagnosis in patients with presumed ADPKD when the patient appears to be a spontaneous mutation, is older without liver cysts, has radiologically detectable solid masses as well as cysts, and of course when any pathognomonic findings of TS are present. The cysts in TS have a unique lining with eosinophilic and nodular hyperplastic epithelium [6] . Renal failure can result from extensive involvement of both angiomyolipoma and cysts but is more common with polycystic kidneys [6, 105] . In one study, renal disease was the most common cause of death occurring in patients older than 10 years and increased in frequency with advancing age [108] .
Management recommendations are to periodically monitor TS patients with MRI of the brain, renal ultrasonography, renal function studies, and chest X-ray, because most causes of death result from potentially treatable causes [102] . In patients presenting predominantly as polycystic kidney disease, screening for other clinical features of TS is important to verif' the diagnosis.
Von-Hippel-Lindau disease Epidemiology and genetics. Von-Hippel-Lindau disease (VHL) is a rare (about 1:36000 live births) autosomal dominant disease characterized by multiple tumors, most often retinal angiomas, CNS and spinal haemangioblastomas, renal cell carcinomas and pheochromocytomas. Cysts in kidneys, pancreas and epididymis are also frequent findings [109] . Penetrance is more than 90% by age 60 years [109] . Linkage of the VHL disease gene to markers on the short arm of chromosome 3 was reported in 1988, and subsequently linkage analysis was shown to accurately predict gene carrier status in 88% of asymptotnatic members of disease families [1101. There is no evidence for genetic heterogeneity [110] , and new mutations seem to be uncommon (less than 10%) [109] . Recently, the VHL gene itself, a tumor suppressor gene, was identified [8] . Interestingly, renal cell carcinoma cell lines obtained from patients with sporadic renal cell carcinoma showed mutations in the same tumor suppressor gene [8] .
Diagnosis, clinical manifestations and management considerations. The diagnosis in a family member is made when one or more disease manifestations are present [110] . When there is no family history, two or more hemangioblastomas or one hemangioblastoma and one visceral manifestation are required for diagnosis [1091. The mean age at onset in one study was 26.3 years, with retinal angioma as the first manifestation in 43% of patients, cerebellar hemangioblastoma in 39%, and renal cell carcinoma in 10% [109] . Renal cysts occur in up to 76% of patients and may be detected in the second decade, whereas renal carcinomas usually occur at a mean age of 44 years [109] . Renal cell carcinomas can be present in patients who also have cysts [7] .
The carcinomas are often multiple and bilateral and occur at younger ages than tumors in the general population. Renal carcinoma was the leading cause of death in one study, accounting for 47% of all deaths [109] .
Some VHL families have a high incidence of pheochromocytoma. Conversely when unselected patients with pheochromocytoma were screened, 19% were found to be carriers of VHL [11 1], Pancreatic and epididymal cysts appear to be common, although their exact incidence is not known [109] .
Gadolinium-enhanced MRI of the brain, ophthalmoscopy, and CT of the abdomen are considered the best screening procedures for family members who may be gene carriers [111, 112] . The management of renal cystic disease is not clear because of the possibility of coexisting carcinoma even in benign-appearing cysts.
Bilateral nephrectomy versus a conservative approach with regular screening and tumor enucleation have both been advocated.
Autosomal-recessive polycystic kidney disease Epidemiology and genetics. ARPKD is a rare genetic disorder with reported incidence from 1:6000 to 1:55,000 in various studies [113, 114] . Given the autosomal recessive inheritance, the parents are always unaffected and each offspring has a one in four chance of inheriting the defective gene from each carrier parent and hence the disease. A gene for ARPKD has been located on chromosome 6 (note added in proof, B). Therefore, linkage studies for diagnosis are now available. No genetic heterogeneity was found in the first 16 families studied (note added in proof, B).
Since the disease can present from perinatal life to early adulthood, four distinct genetic entities had been proposed in the past, based on the age at presentation: perinatal, neonatal, infantile and juvenile [115] . However, the observation of different ages of presentation in siblings from the same family led to the view that there is one causative gene [116] [117] [118] . Linkage analysis in more families will provide further information on this. All affected children have both renal and hepatic abnormalities, but younger children have a predominance of the renal disease and older children and adolescents manifest more significant hepatic disease [114, [117] [118] [119] .
Diagnosis, clinical manifestations and management considerations. The diagnosis is usually made by imaging studies of the child. Characteristic ultrasonographic findings prenatally and in young children are enlarged, hyperechoic kidneys with poor differentiation between cortex and medulla. However, these signs are not specific since they can also be seen prenatally or in infants with ADPKD [114, 117, 120] . Older children with ARPKD can develop macrocysts, and the appearance of the kidneys on US can resemble ADPKD. Other less common entities can also have a similar radiographic appearance to ADPKD [119] . The differentiation between ARPKD and ADPKD depends heavily upon the ultrasonographic findings in the parents. Providing non-paternity has been excluded, the finding of a normal ultrasonogram in both parents, particularly if they are over thirty years of age, supports the diagnosis of ARPKD. When parents are not available for study or have equivocal findings, biopsy of the patient's kidneys or liver may be required to establish the diagnosis of ARPKD [119] . Although ultrasonographic similarities exist between ARPKD and ADPKD, pathologically the disorders are distinct both in the kidneys and the liver. The kidneys in ARPKD display numerous small fusiform cysts, generally 1 to 8 mm in size, in the medulla and cortex (Fig. 4) . These cysts arise from dilated distal tubules and collecting tubules and are aligned in a radial distribution ( I. It Although prenatal diagnosis by US has been possible as early as the 14th week of gestation [121] , often renal abnormalities become apparent only in the third trimester [114, 121] , and both false negative and false positive prenatal ultrasound diagnoses have been reported [121, 122] , the latter particularly if there is no prior family history [123] . Moreover, even severe prenatal abnormalities do not necessarily predict a fatal outcome [124] . For a clinician it is most important to remember that not all renal cystic disease presenting in utero, infancy or childhood is ARPKD.
Most patients present at birth or in early infancy, most commonly with abdominal masses due to the enlarged kidneys [114, 118, 1251 . Some of these severely affected children still die in the first month of life of respiratory failure due to pulmonary hypoplasia [114, 118, 119] . Children who survive the neonatal period often have adequate renal function for many years [118, 119, 126] , although they always have decreased urinary concentrating capacity. Hypertension is common and often severe, requiring therapy in early childhood [114, 118, 119, 126] . In older children and adolescents signs of liver involvement with hepatosplenomegaly, portal hypertension and bleeding esophageal varices predominate over the renal disease; liver function tests, however, are always normal [117, 119] , unless cholangitis supervenes.
Management is directed at the renal and hepatic complications and includes treatment of hypertension and urinary tract infections and renal replacement therapy with dialysis and transplantation. The complications of portal hypertension may require esophageal scierotherapy or portacaval shunting. With modern treatment modalities the prognosis is not as grim as previously reported. In one study the life-table survival rate was 46% at 15 years for all children and 79% at 15 years for those who had survived the first year of life [125] .
Juvenile nephronophthisis-Medullaiy cystic disease Epidemiology and genetics. Two different terms, juvenile nephronophthisis (JN) and medullary cystic disease (MCD), have been used for diseases with similar renal morphology but different types of inheritance, ages of onset, and associated abnormalities. Both disorders are characterized by slowly progressive renal insufficiency with shrunken kidneys, and histologically by prominent, diffuse interstitial lesions [127] . It is probable that different genes are responsible for the two entities. JN shows an autosomal recessive inheritance, presents in childhood, and progresses to ESRD before the age of 25, whereas MCD shows an autosomal dominant inheritance and presents later in life, up to the fourth or fifth decade [127] [128] [129] . Recent linkage studies have mapped the gene for JN to chromosome 2p, whereas linkage for Senior-Loken syndrome, which is nephronophthisis with retinal degeneration, was not linked to this site [130, 131] . Another phenotypic form has accounts for 10 to 32% of ESRD in children [127] , it appears that in large populations it accounts for 2.4% of childhood ESRD [133] , The autosomal dominant form of medullary cystic disease seems to be very rare [127] . Diagnosis, clinical manifestations and management considerations. Children with this disease have an early urinary concentrating defect leading to polydipsia and polyuria and slowly progressive renal failure accompanied by growth retardation, anemia and hypertension in advanced stages. Heavy proteinuria and hematuria are usually absent. Prominent salt wasting has been reported in some cases [127, 134] . Diagnosis is difficult because most findings are nonspecific; ultrasonography shows kidneys of normal or reduced size, loss of corticomedullary differentiation, and sometimes medullary cysts; however, usually these are found only in advanced stages [127] . Abdominal CT was shown in one case report to be diagnostic, revealing multiple cysts up to 5 mm in diameter throughout the medulla of both kidneys, whereas US had been nonspecific [135] . Percutaneous biopsy usually shows a tubulointerstitial nephropathy with atrophic tubules with segments of markedly thickened basement membrane as well as segments of thinned basement membranes [20] ; the cysts are often missed with biopsy.
Extrarenal manifestations have been reported in association with JN, including congenital hepatic fibrosis [136] [137] [138] [139] [140] [141] , tapetoretinal degeneration, mental retardation, cerebellar dysfunction and skeletal abnormalities [127] , but these may represent other genetic disorders. None of these associations have been found in the dominant form of medullary cystic disease [1271. Since there is no specific therapy, management is directed at avoiding and treating complications of progressive renal insufficiency. Renal transplantation is the treatment of choice for children with ESRD due to JN; recurrence has never been observed.
Medullaty sponge kidney
Medullary sponge kidney (MSK) is characterized by nonprogressive dilatation of collecting ducts and tubules, sometimes associated with multiple small cysts, in one or more renal papillae. Although autosomal dominant inheritance has been reported in a minority of cases, the disorder is more often seen sporadically.
The pathogenesis is thought to be due to a developmental abnormality [142] , and other associated developmental and genetic disorders including congenital hemihypertrophy, EhiersDanlos and Marfan's syndrome, Caroli's disease and ADPKD have been described in patients with MSK [142, 143] . The diagnosis is made by excretory urography which shows typical brush-like linear striations or spherical cystic lesions of the renal papillae; difficulties in diagnosing MSK arise when only one or two papillae are involved or when the urogram is not of high quality [142] . The prevalence in unselected patients undergoing excretory urography is 0.5 to 1% [142, 144] ; both sexes appear to be equally affected.
Although MSK is often asymptomatic, clinical manifestations can include hematuria, infections and nephrolithiasis. The latter is a particularly interesting association. The prevalence of MSK among stone patients has been reported between 12% [144] and 21% [142] . The pathogenetic factors responsible for the association with nephrolithiasis and nephrocalcinosis are not entirely clear. One study found metabolic disorders accounting for the nephrolithiasis in 93% of stone patients without MSK but in only 60% of stone patients with MSK, concluding that MSKper se is a cause for nephrolithiasis [144] . In another study the composition of stones was found to be similar in patients with or without MSK [145] . Urinary stagnation in the dilated collecting ducts, subtle acidification defects, hypercalciuria and hyperoxaluria all have been implicated as contributing to stone formation in patients with MSK [1421. Some authors have reported an association of primary hyperparathyroidism with MSK [146] , but others view evidence for a direct association as still insufficient [142] .
Management of urolithiasis and nephrocalcinosis in MSK patients does not differ from that of stone patients of the general population. ESWL has been used in MSK patients with good success and without major complications [147, 148] ; thiazides prevent new calcium stone formation in normocalciuric as well as hypercalciuric patients. If infections and nephrolithiasis are treated appropriately, MSK does not lead to renal insufficiency.
Acquired renal cystic disease
Several types of renal cysts are acquired. The most common type is simple renal cysts which are rare in children but increase in frequency with age. In a recent study unilateral cysts occurred in 1.7% of normal patients 30 to 49 years old, in 11.5% of those 50 to 70 years old and in 22% of those over seventy [149] . Bilateral cysts were observed in 1, 4, and 9% of these age groups, respectively [149] . Usually they are asymptomatic and are detected as an incidental finding on an ultrasound study where they show smooth walls and no intracystic echoes. Occasionally they can bleed causing flank pain and/or hematuria. CT scanning is recommended in such cases to exclude malignancy.
Another form of acquired renal cysts is associated with hypokalemia. Patients with primary hyperaldosteronism were found by CT scanning to have bilateral renal cysts, predominantly in the medulla, more often than age-matched control patients with essential hypertension [32] . Moreover, the cysts regressed after resection of an adrenal adenoma [32] . The pathogenesis is not clear, but hypokalemia may stimulate tubular cells to proliferate [150] .
The term acquired cystic kidney disease (ACKD) usually refers to the development of cysts in the kidneys of chronic renal failure e.g. liver cysts, heart valve abnormalities, intracranial aneurysms, diverticula "skin, brain, heart, retina retina, brain, phaeochromocytoma patients with underlying non-cystic renal disorders. Other organs are not affected. Epidemiology of ACKD. Acquired renal cysts can be found in 7 to 22% of chronic renal failure patients before the start of dialysis therapy, but their frequency increases with increasing duration of dialysis [151] . About 44% of patients treated for less than three years, 80% of those treated for more than four years and 90% of those on dialysis for more than 10 years develop ACKD, with similar incidence for hemodialysis and peritoneal dialysis patients [151, 152] . Children with long standing renal failure or on long-term dialysis can also develop ACKD [151] [152] [153] . The severity of ACKD manifests as increasing cyst numbers and renal volumes with increased duration of dialysis treatment [154] . After successful transplantation ACKD regresses in some but not lI patients. In one study, 18% of renal allograft recipients had an increase in cyst numbers in their native kidneys despite long-standing good transplant function [155] , and another study found an increased prevalence of ACKD among transplant recipients treated with cyclosporin A [156] . Some but not all studies have demonstrated an increased frequency of ACKD in males than in females [151, 152, 157] . An overrepresentation of black ESRD patients with ACKD has been reported [1521.
Diagnosis, clinical manifestations and management considerations. Diagnosis can be made by renal ultrasonography; however, since the kidneys and cysts are often small, CT scanning may be more sensitive [152, 154] . Usually ACKD is asymptomatic, but painful cyst hemorrhage, retroperitoneal hemorrhages, and infection can occur. Rarely, kidneys with ACKD can enlarge significantly, particularly when a previous unilateral nephrectomy has been performed, and thus mimic ADPKD with symptoms of heaviness and pain [158] , The most serious complication is renal cell carcinoma (RCC), which is best diagnosed by contrastenhanced CT-scanning. Two prospective studies examining the incidence of RCC have been reported. One from Japan found 2 RCC among 57 patients over a 10 year period [159] ; the other from the USA also found 2 RCC among 30 patients over 7 years [154] . Therefore, the annual incidence of RCC in dialysis patients is about 3 to 6 times greater as compared with an age-matched general population [160] . The incidence of RCC increases with duration of dialysis and with increasing severity of ACKD, and males are 4 to 7 times more often affected than females [151, 152, 1601 . In up to 86% of cases RCC are asymptomatic, and therefore annual screening of dialysis patients by CT has been recommended by some authors [151] . On the other hand, RCC is a relatively rare cause of death in dialysis patients, and their life expectancy if often reduced by concomitant, particularly cardiovascular, diseases; moreover, often these patients are poor candidates for major surgery if RCC is detected by screening. Therefore, it has been questioned whether regular screening of all patients would have a significant impact on patient survival [160] .
This needs to be considered in light of the substantial cost.
Probably it is best to screen selected patients who are young, in general good condition and have risk factors for RCC such as long duration of dialysis, significant ACKD and large kidneys, particularly if they are male [160] .
Approach to the patient with cystic disease. This array of cystic disease may seem like a maze, but it is a maze with many clues to direct the physician to the correct diagnosis in a given patient (Tables 4 and 5 ). The family history including autopsy data, questions about consanguinity and construction of a pedigree are important first steps; often ultrasonographic information on the family is needed. This information serves to determine if there is a familial aspect to the disorder and if transmission is compatible with autosomal dominant inheritance. Consanguinity increases the likelihood of a recessive disorder. The patient's age, blood pressure, renal size and function and the extrarenal manifestations point the way to the correct diagnosis. Utilizing the information supplied in Table 5 one can see which of these manifestations are compatible with the various cystic diseases. Thus, not all entities would be entertained in a specific patient. For example, in a patient with a strong family history of cystic renal disease, ACKD and MSK are not likely to be the disorders, In a patient with large kidneys, the medullasy cystic diseases and simple cysts would be excluded; similarly in patients with renal failure simple cysts, VHL, and medullary sponge kidney would be extremely unlikely candidates. In contrast, certain entities should always be considered together. In a child with large kidneys, particularly if other family members are affected, ADPKD, ARPKD and TS should all be considered. In some patients diagnosis remains difficult. For example, the 22 year old patient in an ADPKD family with a single cyst as her sole abnormality who wishes to donate her kidney to an affected brother and who has no other living affected family members cannot be definitively diagnosed as having ADPKD or a simple cyst. The answers to these dilemmas await the evolution of the disease and/or the evolution of our understanding and diagnostic armamentarium. 
